Oruka Therapeutics, Inc. (ORKA) stock
ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
$96.32−2.92 (-2.94%)
Close on Nov 17, 2026Market cap $6.38BP/E –Yield –
Earnings
Oruka Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2024
–
EPS, Q2 FY2024
-$0.18
-$0.10 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Oruka Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026after the close | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024after the close | – | – | -$0.18 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 25, 2024after the close | – | – | -$0.14 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 1, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 18, 2023after the close | – | – | -$0.10 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 21, 2023after the close | – | – | -$0.10 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 24, 2023after the close | – | – | -$0.09 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 24, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 28, 2022after the close | – | – | -$0.16 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022after the close | – | – | -$0.22 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 2, 2022after the close | – | – | -$0.23 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 14, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021after the close | – | – | -$0.33 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 11, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 18, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 2, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 6, 2020after the close | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Feb 18, 2020after the close | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 6, 2019after the close | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 1, 2019after the close | – | – | – | Filing |
| Q1 FY2019ended Mar 31, 2019 | May 8, 2019after the close | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Feb 20, 2019before the open | – | – | – | Filing |
| Q3 FY2018ended Sep 30, 2018 | Nov 14, 2018after the close | – | – | – | Filing |
| Q2 FY2018ended Jun 30, 2018 | Aug 9, 2018after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Oruka Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Oruka Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Oruka Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Results
- Update
- Update
- Update
- Update
- News
- Update
- Update
- Results
- Results
- Results
- News
See a number that looks wrong?